Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$16.15 - $42.35 $13,307 - $34,896
-824 Reduced 1.1%
74,001 $1.2 Million
Q2 2023

Aug 14, 2023

BUY
$40.29 - $82.51 $3.01 Million - $6.17 Million
74,825 New
74,825 $3.11 Million
Q4 2020

Feb 12, 2021

SELL
$112.16 - $174.14 $85.6 Million - $133 Million
-762,811 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$58.05 - $111.31 $58.4 Million - $112 Million
-1,006,718 Reduced 56.89%
762,811 $84.9 Million
Q2 2020

Aug 14, 2020

BUY
$57.2 - $74.41 $46.2 Million - $60.1 Million
807,659 Added 83.97%
1,769,529 $105 Million
Q1 2020

May 14, 2020

BUY
$57.05 - $95.75 $5.68 Million - $9.53 Million
99,520 Added 11.54%
961,870 $64.8 Million
Q4 2019

Feb 11, 2020

BUY
$68.3 - $93.8 $58.9 Million - $80.9 Million
862,350 New
862,350 $72.7 Million

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $1.79B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.